In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation
- PMID: 18074444
- DOI: 10.1016/j.ejphar.2007.07.070
In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation
Abstract
The prolongation of the ventricular repolarization and proarrhythmic effects (Torsade de Pointes: TdP) of five reference antibiotics were compared in four in-vitro models. 1. Using the patch clamp technique on the human ether-a-gogo-related gene (HERG) current, the rank order for blockade of the HERG-current (IC(50)) was: sparfloxacin (44 microM)>telithromycin=moxifloxacin=erythromycin (+/-100 microM). 2. Assessing their effects on action potential duration (APD(90)) and incidence of early afterdepolarizations in isolated rabbit Purkinje fibers, the rank order was: sparfloxacin>moxifloxacin>telithromycin>erythromycin (prolongation of APD(90) at 100 microM: 83%, 48%, 33% and 17% from baseline compared to +5% with solvent, P<0.05, respectively). 3. Assessing the drug effects on the APD(60), triangulation, reverse use-dependency, and instability in isolated Langendorff-perfused rabbit hearts, the rank order was: moxifloxacin>erythromycin>sparfloxacin>telithromycin. 4. Assessing their torsadogenic potentials (scores of effects on QT-interval, peak of the T wave to end of T wave: T(p-e), T(p-e)/QT ratio, R wave on T wave (R on T) and TdP in isolated rabbit left ventricular wedge preparations, the rank order for their TdP risk score was: sparfloxacin>erythromycin>moxifloxacin>telithromycin. Additional experiments with grepafloxacin indicate that the rank order to detect grepafloxacin-induced long QT was the wedge preparation>the Purkinje fiber>HERG>the isolated heart, where the isolated heart was unable to detect grepafloxacin-induced APD prolongation. The present study demonstrates that the first three in-vitro models can be used to assess the ability of antibiotic compounds to delay ventricular repolarization. However, with respect to their known clinical effects on QT and TdP incidence, the wedge preparation appears to be more predictive and suitable for detecting torsadogenic action of antibiotics.
Corrected and republished from
-
In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.Eur J Pharmacol. 2006 Dec 28;553(1-3):229-39. doi: 10.1016/j.ejphar.2006.09.035. Epub 2006 Sep 23. Eur J Pharmacol. 2006. Corrected and republished in: Eur J Pharmacol. 2007 Dec 22;577(1-3):222-32. doi: 10.1016/j.ejphar.2007.07.070. PMID: 17054943 Corrected and republished.
Similar articles
-
In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.Eur J Pharmacol. 2006 Dec 28;553(1-3):229-39. doi: 10.1016/j.ejphar.2006.09.035. Epub 2006 Sep 23. Eur J Pharmacol. 2006. Corrected and republished in: Eur J Pharmacol. 2007 Dec 22;577(1-3):222-32. doi: 10.1016/j.ejphar.2007.07.070. PMID: 17054943 Corrected and republished.
-
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.J Cardiovasc Pharmacol. 2001 May;37(5):607-18. doi: 10.1097/00005344-200105000-00012. J Cardiovasc Pharmacol. 2001. PMID: 11336111
-
Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):90-105. doi: 10.1016/j.vascn.2005.04.007. J Pharmacol Toxicol Methods. 2005. PMID: 15978848
-
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.Cardiovasc Res. 2003 Apr 1;58(1):32-45. doi: 10.1016/s0008-6363(02)00846-5. Cardiovasc Res. 2003. PMID: 12667944 Review.
-
Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.J Pharmacol Toxicol Methods. 2006 Mar-Apr;53(2):87-105. doi: 10.1016/j.vascn.2005.07.003. Epub 2005 Nov 11. J Pharmacol Toxicol Methods. 2006. PMID: 16289936 Review.
Cited by
-
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.Br J Pharmacol. 2008 Aug;154(7):1427-38. doi: 10.1038/bjp.2008.191. Epub 2008 May 19. Br J Pharmacol. 2008. PMID: 18493243 Free PMC article.
-
Increasing gap junction coupling suppresses ibutilide-induced torsades de pointes.Exp Ther Med. 2014 May;7(5):1279-1284. doi: 10.3892/etm.2014.1601. Epub 2014 Mar 4. Exp Ther Med. 2014. PMID: 24940425 Free PMC article.
-
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.Assay Drug Dev Technol. 2010 Dec;8(6):727-42. doi: 10.1089/adt.2010.0331. Assay Drug Dev Technol. 2010. PMID: 21158687 Free PMC article.
-
The electro-mechanical window in anaesthetized guinea pigs: a new marker in screening for Torsade de Pointes risk.Br J Pharmacol. 2012 May;166(2):689-701. doi: 10.1111/j.1476-5381.2011.01795.x. Br J Pharmacol. 2012. PMID: 22122450 Free PMC article.
-
Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.Br J Pharmacol. 2012 Jul;166(5):1694-707. doi: 10.1111/j.1476-5381.2012.01874.x. Br J Pharmacol. 2012. PMID: 22289150 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical